BeiGene Ltd.
ISIN US07725L1026
|WKN A1437N
Overview
Description
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Healthcare Biopharmaceuticals Non-System-Specific Biopharmaceuticals Cayman Islands
Financials
Key metrics
| Market capitalisation, EUR | 20,727.28 m |
| EPS, EUR | -7.60 |
| P/B ratio | 6.03 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2023)
| Revenue, EUR | 2,274.33 m |
| Net income, EUR | -815.57 m |
| Profit margin | -35.86% |
What ETF is BeiGene Ltd. in?
There are 11 ETFs which contain BeiGene Ltd.. All of these ETFs are listed in the table below. The ETF with the largest weighting of BeiGene Ltd. is the First Trust NYSE Arca Biotechnology UCITS ETF Acc.
| ETF | Weight | Investment focus | Holdings | TER | Fund size (in m EUR) | Return 1Y | WKN | ISIN |
|---|---|---|---|---|---|---|---|---|
| L&G Global Thematic ESG Exclusions UCITS ETF USD Accumulating | 0.61% | Equity World Social/Environmental Innovation | 358 | 0.60% | 4 | +16.15% | A3DHPA | IE000VTOHNZ0 |
| Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 1.12% | Equity World Health Care Social/Environmental Innovation | 97 | 0.30% | 3 | +13.13% | DBX0R2 | IE000KD0BZ68 |
| L&G Gerd Kommer Multifactor Equity UCITS ETF USD Distributing | 0.05% | Equity World Multi-Factor Strategy | 3,620 | 0.50% | 62 | +24.68% | WELT0B | IE000FPWSL69 |
| iShares Dow Jones China Offshore 50 UCITS ETF (DE) | 1.06% | Equity China | 50 | 0.61% | 51 | +17.68% | A0F5UE | DE000A0F5UE8 |
| iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) | 0.99% | Equity United States Health Care Biotech | 214 | 0.35% | 32 | +19.86% | A2JDYM | IE00BDZVHG35 |
| L&G Gerd Kommer Multifactor Equity UCITS ETF USD Accumulating | 0.05% | Equity World Multi-Factor Strategy | 3,620 | 0.50% | 325 | +25.13% | WELT0A | IE0001UQQ933 |
| iShares Nasdaq US Biotechnology UCITS ETF | 0.99% | Equity United States Health Care Biotech | 214 | 0.35% | 440 | +20.83% | A2DWAW | IE00BYXG2H39 |
| First Trust NYSE Arca Biotechnology UCITS ETF Acc | 4.58% | Equity United States Health Care Biotech | 30 | 0.60% | 7 | +20.50% | A2PZBP | IE00BL0L0H60 |
| Invesco Nasdaq Next Generation 100 UCITS ETF Acc | 0.64% | Equity United States Technology | 102 | 0.25% | 43 | +28.92% | A2QPVX | IE00BMD8KP97 |
| HSBC MSCI AC Asia Pacific ex Japan Climate Paris Aligned UCITS ETF | 0.00% | Equity Asia Pacific Social/Environmental Climate Change | 325 | 0.25% | 17 | +20.75% | A3C8ZY | IE000XFORJ80 |
| L&G Pharma Breakthrough UCITS ETF | 3.08% | Equity World Health Care Innovation | 37 | 0.49% | 15 | +4.47% | A2H9XR | IE00BF0H7608 |
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.